PL1940817T3 - Środki pobudzające układ cholinergiczny o ulepszonej przenikalności przez barierę krew-mózg do leczenia chorób z towarzyszącym upośledzeniem funkcji poznawczych - Google Patents
Środki pobudzające układ cholinergiczny o ulepszonej przenikalności przez barierę krew-mózg do leczenia chorób z towarzyszącym upośledzeniem funkcji poznawczychInfo
- Publication number
- PL1940817T3 PL1940817T3 PL06792225T PL06792225T PL1940817T3 PL 1940817 T3 PL1940817 T3 PL 1940817T3 PL 06792225 T PL06792225 T PL 06792225T PL 06792225 T PL06792225 T PL 06792225T PL 1940817 T3 PL1940817 T3 PL 1940817T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- brain barrier
- cognitive impairment
- improved blood
- barrier permeability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05020721A EP1777222A1 (en) | 2005-09-22 | 2005-09-22 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| US78024306P | 2006-03-07 | 2006-03-07 | |
| EP06792225A EP1940817B1 (en) | 2005-09-22 | 2006-09-22 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| PCT/EP2006/009220 WO2007039138A1 (en) | 2005-09-22 | 2006-09-22 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1940817T3 true PL1940817T3 (pl) | 2011-03-31 |
Family
ID=35717553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06792225T PL1940817T3 (pl) | 2005-09-22 | 2006-09-22 | Środki pobudzające układ cholinergiczny o ulepszonej przenikalności przez barierę krew-mózg do leczenia chorób z towarzyszącym upośledzeniem funkcji poznawczych |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080261954A1 (pl) |
| EP (2) | EP1777222A1 (pl) |
| CN (1) | CN101287719A (pl) |
| CA (1) | CA2623114A1 (pl) |
| DK (1) | DK1940817T3 (pl) |
| ES (1) | ES2348334T3 (pl) |
| PL (1) | PL1940817T3 (pl) |
| PT (1) | PT1940817E (pl) |
| SI (1) | SI1940817T1 (pl) |
| WO (1) | WO2007039138A1 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| DK2137192T3 (da) * | 2008-04-14 | 2014-05-26 | Neurodyn Life Sciences Inc | Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme |
| HRP20171415T4 (hr) | 2009-06-25 | 2023-03-03 | Alkermes Pharma Ireland Limited | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja |
| WO2010151711A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
| AU2010275431A1 (en) * | 2009-07-23 | 2012-02-23 | Shire Llc | Galantamine amino acid and peptide prodrugs and uses thereof |
| EP2585066B1 (en) | 2010-06-24 | 2018-09-26 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| US9034867B2 (en) | 2011-03-18 | 2015-05-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
| NZ722096A (en) | 2011-12-15 | 2016-11-25 | Alkermes Pharma Ireland Ltd | Prodrugs of secondary amine compounds |
| JP6471089B2 (ja) | 2012-03-19 | 2019-02-13 | アルカームス ファーマ アイルランド リミテッド | 脂肪酸エステルを含む医薬組成物 |
| JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
| CA2867137C (en) | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol |
| PT3417862T (pt) | 2012-07-27 | 2021-08-06 | Neurodyn Life Sciences Inc | Biodisponibilidade cerebral da galantamina melhorada através de formulações selecionadas e administração transmucosal de pró-fármacos lipofílicos |
| ES2792149T3 (es) | 2012-09-19 | 2020-11-10 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada |
| CN103193787B (zh) * | 2013-03-11 | 2015-10-28 | 华中科技大学 | 具有神经保护作用的石蒜伦碱类化合物及其制备方法 |
| CN103204860B (zh) * | 2013-03-11 | 2015-10-28 | 华中科技大学 | 具有神经保护作用的石蒜科生物碱类化合物 |
| MX2016012041A (es) | 2014-03-20 | 2017-01-19 | Alkermes Pharma Ireland Ltd | Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion. |
| US11219627B2 (en) * | 2014-05-16 | 2022-01-11 | Synaptec Development Llc | Clearance of amyloid beta |
| JP7384812B2 (ja) | 2018-03-05 | 2023-11-21 | アルカームス ファーマ アイルランド リミテッド | アリピプラゾール投与戦略 |
| EP4029867A1 (en) | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
| EP4186509A1 (en) | 2021-11-26 | 2023-05-31 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| ATE411026T1 (de) * | 1987-05-04 | 2008-10-15 | Bonnie Davis | Mittel zur behandlung der alzheimer-krankheit |
| US4981849A (en) * | 1989-02-23 | 1991-01-01 | Smithkline Beecham Corporation | Alpha-adrenergic receptor antagonists |
| ATE183084T1 (de) * | 1991-05-14 | 1999-08-15 | Ernir Snorrason | Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren |
| US6323195B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| US6323196B1 (en) * | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
| AT403803B (de) * | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| AU8742198A (en) * | 1997-08-15 | 1999-03-08 | Shire International Licensing B.V. | Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity |
| ATE306264T1 (de) * | 1998-12-11 | 2005-10-15 | Bonnie M Davis | Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen- gonadenachse |
| JP4721386B2 (ja) * | 2001-07-10 | 2011-07-13 | 第一三共株式会社 | 新規ガランタミン類縁体 |
| US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| US20040266659A1 (en) * | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
-
2005
- 2005-09-22 EP EP05020721A patent/EP1777222A1/en not_active Withdrawn
-
2006
- 2006-09-22 PL PL06792225T patent/PL1940817T3/pl unknown
- 2006-09-22 EP EP06792225A patent/EP1940817B1/en not_active Revoked
- 2006-09-22 WO PCT/EP2006/009220 patent/WO2007039138A1/en active Application Filing
- 2006-09-22 PT PT06792225T patent/PT1940817E/pt unknown
- 2006-09-22 ES ES06792225T patent/ES2348334T3/es active Active
- 2006-09-22 CN CNA2006800351514A patent/CN101287719A/zh active Pending
- 2006-09-22 DK DK06792225.2T patent/DK1940817T3/da active
- 2006-09-22 US US12/067,799 patent/US20080261954A1/en not_active Abandoned
- 2006-09-22 SI SI200630770T patent/SI1940817T1/sl unknown
- 2006-09-22 CA CA002623114A patent/CA2623114A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007039138A1 (en) | 2007-04-12 |
| US20080261954A1 (en) | 2008-10-23 |
| SI1940817T1 (sl) | 2010-10-29 |
| PT1940817E (pt) | 2010-10-11 |
| CN101287719A (zh) | 2008-10-15 |
| ES2348334T3 (es) | 2010-12-02 |
| EP1777222A1 (en) | 2007-04-25 |
| CA2623114A1 (en) | 2007-04-12 |
| EP1940817B1 (en) | 2010-07-07 |
| EP1940817A1 (en) | 2008-07-09 |
| DK1940817T3 (da) | 2010-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1940817T1 (sl) | Holinergični ojačevalci z izboljšano hematoencefalno barierno propustnostjo za zdravljenje bolezni, ki spremljajo upad kognitivnih sposobnosti | |
| EP1972098A4 (en) | ROAMING QUERIES BEFORE ALLOCATION / AUTHENTICATION | |
| GB0518390D0 (en) | Therapeutic compounds | |
| IL195330A0 (en) | Permeability of blood-brain barrier | |
| GB0518237D0 (en) | Therapeutic compounds | |
| IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
| SI2001892T1 (sl) | Spojine imidazolotiazol za zdravljenje proliferacijskih bolezni | |
| GB0509326D0 (en) | Therapeutic compounds | |
| GB0509573D0 (en) | Therapeutic compounds | |
| ZA200708858B (en) | Pharmacokinetically improved compounds | |
| GB0518361D0 (en) | Therapeutic compounds | |
| GB0522881D0 (en) | Therapeutic compounds | |
| IL208070A0 (en) | Myxoma virus mutants for therapeutic treatment | |
| IL183379A0 (en) | Processes for the preparation of linezolid intermediate | |
| EP1862153A4 (en) | OPHTHALMIC CANNULA | |
| FR2894432B1 (fr) | Ameliorant de panification | |
| GB0522130D0 (en) | Therapeutic compounds | |
| GB0526107D0 (en) | Therapeutic Compounds | |
| GB0518235D0 (en) | Therapeutic compounds | |
| EP2631646A4 (en) | BIOMARKER FOR MORBUS ALZHEIMER OR LIGHT COGNITIVE IMPAIRMENT | |
| IL190182A0 (en) | 2-aminoalcohols for the treatment of neurodegenerative diseases | |
| IL185344A0 (en) | Pharmacokinetically improved compounds | |
| GB0500823D0 (en) | Privacy shields | |
| ES1060422Y (es) | Almohada terapeutica de cascara de alforfon. | |
| GB0515580D0 (en) | Therapeutic compounds |